Resigratinib

Overview of the drug Resigratinib

Resigratinib
File:Resigratinib.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Resigratinib is a small molecule tyrosine kinase inhibitor that has been investigated for its potential use in the treatment of various types of cancer. It is known for its ability to target specific kinases involved in the signaling pathways that regulate cell growth and survival.

Mechanism of Action

Resigratinib functions by inhibiting the activity of certain tyrosine kinases, which are enzymes that play a critical role in the signaling pathways that control cell division and survival. By blocking these kinases, resigratinib can interfere with the growth and proliferation of cancer cells. This makes it a promising candidate for targeted cancer therapy, particularly in cancers where these kinases are overactive.

Clinical Development

Resigratinib has undergone various stages of clinical trials to evaluate its safety and efficacy. These trials are designed to determine the optimal dosing, assess potential side effects, and evaluate the drug's effectiveness in treating specific types of cancer. The results of these trials will determine whether resigratinib can be approved for clinical use.

Potential Indications

Resigratinib is being studied for its potential use in treating several types of cancer, including:

• Non-small cell lung cancer (NSCLC)
• Breast cancer
• Colorectal cancer

The drug's ability to target specific kinases makes it a candidate for personalized medicine approaches, where treatment is tailored to the genetic profile of the patient's tumor.

Side Effects

As with many cancer therapies, resigratinib may cause side effects. Common side effects observed in clinical trials include:

• Fatigue
• Nausea
• Diarrhea
• Skin rash

More serious side effects may occur, and patients receiving resigratinib are closely monitored for any adverse reactions.

Research and Development

Research on resigratinib is ongoing, with studies focusing on understanding its full range of activity, optimizing its use in combination with other therapies, and identifying biomarkers that predict response to treatment. The development of resigratinib is part of a broader effort to create more effective and less toxic cancer treatments.

Related Pages

• Tyrosine kinase inhibitor
• Cancer treatment
• Targeted therapy